Clinical trials: Infection Reactivation
- Condition Infection Reactivation
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Whooping Cough
Viaskin Pertussis Vaccine Trial
The study is a Phase I, first in human, monocenter study, aiming at assessing the safety and immunogenicity of a genetically detoxified pertussis toxin (PT) when administered via the cutaneous route with Viaskin patches to…
- Trial name
- NCT03035370
- Testing
- Viaskin PT 25 mcg, Viaskin PT 50 mcg, Boostrix™
- Where
- Switzerland
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- DBV Technologies
Epstein-Barr Virus (EBV), Healthy Volunteers
A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years.
- Trial name
- NCT07536048
- Testing
- Investigational Procedure
- Where
- 2 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
ADV Infection Post Allo-HSCT
Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT
Human Adenovirus-specific T-cells can persist and augment impaired adenovirus immune response post allogeneic haematopoietic stem cell transplant, and reduce the requirement for antiviral therapy without toxicity or increasing…
- Trial name
- ASPIRE (NCT01822093)
- Testing
- Cytovir-ADV
- Where
- 3 sites in United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cell Medica Ltd